The American Society of Pain and Neuroscience (ASPN) best practices and guidelines for the interventional management of cancer-associated pain

MM Aman, A Mahmoud, T Deer, D Sayed… - Journal of Pain …, 2021 - Taylor & Francis
Moderate to severe pain occurs in many cancer patients during their clinical course and may
stem from the primary pathology, metastasis, or as treatment side effects. Uncontrolled pain …

[HTML][HTML] Effectiveness and safety of intrathecal drug delivery systems for the management of cancer pain: a systematic review and meta-analysis

R Duarte, S Copley, S Nevitt, M Maden… - … : Technology at the …, 2023 - Elsevier
Objectives Intrathecal drug delivery systems (IDDS) and spinal cord stimulation (SCS) have
been proposed and assessed for the management of cancer pain; however, such treatments …

[PDF][PDF] Rationale and recent advances in targeted drug delivery for cancer pain: is it time to change the paradigm?

D Dupoiron, R Duarte, G Carvajal… - Pain …, 2022 - painphysicianjournal.com
Background: Cancer pain prevalence remains high with more than 60% of patients with
advanced cancer experiencing cancer-related pain. The undertreatment of pain due to …

STING controls opioid-induced itch and chronic itch via spinal tank-binding kinase 1-dependent type I interferon response in mice

N Li, C Wang, Y Zhao, Y Wang, T Gao, Y Yu… - Journal of …, 2023 - Springer
Background Patients receiving epidural or intrathecal opioids administration for neuraxial
analgesia frequently suffer from an irritating itch. STING (stimulator of interferon genes), an …

Refractory cancer pain and intrathecal therapy: critical review of a systematic review

S Mercadante - Pain and Therapy, 2023 - Springer
This critical review assessed the advantages of invasive procedures that were recently
included in systematic reviews, to evaluate whether the definition of refractory pain condition …

Consensus statement on chronic pain treatment in cancer survivors

K Mamiya, H Iida, M Iseki, S Yamaguch… - Journal of …, 2024 - Springer
Abstract In September 2023, the Japanese Society for Palliative Medicine (JSPM) issued
this consensus statement on chronic pain treatment in cancer survivors. With recent …

The Polyanalgesic Consensus Conference (PACC)®: Updates on Clinical Pharmacology and Comorbidity Management in Intrathecal Drug Delivery for Cancer Pain

TR Deer, SM Hayek, JS Grider, JE Pope… - … : Technology at the …, 2024 - Elsevier
Abstract Introduction The International Neuromodulation Society convened a multispecialty
group of physicians based on expertise with international representation to establish …

Management of cancer-related pain with intrathecal drug delivery: a systematic review and meta-analysis of clinical studies

C Perruchoud, D Dupoiron, B Papi, A Calabrese… - … : Technology at the …, 2023 - Elsevier
Background Despite increased attention paid to assessment and management, pain
continues to be a prevalent and undertreated symptom in patients with cancer. Intrathecal …

Initiation of intrathecal drug delivery dramatically reduces systemic opioid use in patients with advanced cancer

JE Sindt, DW Odell, AP Dalley, SE Brogan - … : Technology at the Neural …, 2020 - Elsevier
Objectives Pain is common in cancer, affecting more than 70% of patients with advanced
disease. Intrathecal drug delivery systems (IDDS) are a well-established treatment for …

Early interventional treatments for patients with cancer pain: a narrative review

U Hochberg, P Ingelmo, E Solé, J Miró… - Journal of Pain …, 2023 - Taylor & Francis
Abstract Between 10% and 20% of patients with cancer-related pain cannot achieve
adequate control following the three-step ladder guidelines by the World Health …